A Stellar Recognition in Singapore

In a dazzling ceremony held in Singapore, HaemaLogiX Ltd., an innovative Australian biotech firm, captured the spotlight by winning the prestigious "Most Promising CAR-T Pipeline in APAC" award at the Asia Pacific CGT Excellence Awards 2025 on September 11.

Leading the Charge in CAR-T Therapy

This coveted accolade applauds trailblazing companies demonstrating exceptional innovation and scientific prowess in the emergent CAR T therapy landscape. HaemaLogiX has been recognized as a frontrunner in pioneering CAR T-cell therapies, which are heading towards transforming the treatment journey for patients grappling with multiple myeloma—a pressing health concern across Asia Pacific and the globe.

Visionary Leaders Behind the Innovation

Rosanne Dunn, the Founder and Chief Scientific Officer of HaemaLogiX, expressed her gratitude, saying, "This award validates not only our scientific approach but also the vision and commitment that fuels our efforts. Being acknowledged among such formidable innovators propels us to push boundaries in CAR T-cell therapy, especially for patients with multiple myeloma, a disease that currently lacks a cure.”

Unmasking the Cancer: A Scientific Breakthrough

HaemaLogiX is at the forefront of developing immunotherapies that target unique, untapped antigens on cancerous plasma cells—the kappa myeloma antigen (KMA) and the lambda myeloma antigen (LMA). These breakthroughs ensure precise targeting that minimizes harm to healthy cells, thus preserving the immune system’s integrity—an essential advantage over existing treatment modalities. Remarkably, up to 70% of patients with multiple myeloma are estimated to express KMA while 30% exhibit LMA, highlighting the tailored potential of these therapies.

Understanding Multiple Myeloma

Multiple myeloma is a malignant condition affecting plasma cells in bone marrow and is the second most prevalent blood cancer worldwide, with around 188,000 new diagnoses annually. Alarmingly, about 60% of these patients struggle with standard treatments and often face a grim prognosis, with roughly 42% not surviving beyond five years post-diagnosis. This dire statistic underscores an urgent need for safer and more effective treatment options.

The Future Looks Bright

HaemaLogiX's groundbreaking work opens up new avenues for hope in the fight against multiple myeloma and reflects the transformative potential of CAR T-cell therapies in reshaping patient outcomes in the realm of blood cancers. As the awareness about this condition grows, so too does the anticipation for innovative solutions that promise a new lease on life for countless patients.